TY  - JOUR
AU  - Ruiz de Porras, Vicenç
AU  - Wang, Xieng C
AU  - Palomero, Luis
AU  - Marin-Aguilera, Mercedes
AU  - Solé-Blanch, Carme
AU  - Indacochea, Alberto
AU  - Jimenez, Natalia
AU  - Bystrup, Sara
AU  - Bakht, Martin
AU  - Conteduca, Vincenza
AU  - Piulats, Josep M
AU  - Buisan, Oscar
AU  - Suarez, José F
AU  - Pardo, Juan Carlos
AU  - Castro, Elena
AU  - Olmos, David
AU  - Beltran, Himisha
AU  - Mellado, Begoña
AU  - Martinez-Balibrea, Eva
AU  - Font, Albert
AU  - Aytes, Alvaro
PY  - 2020
DO  - 10.1016/j.eururo.2020.10.001
UR  - http://hdl.handle.net/10668/16558
T2  - European urology
AB  - Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown...
LA  - en
KW  - Combination treatment
KW  - Metastatic castration-resistant prostate cancer
KW  - Platinum
KW  - Taxane resistance
KW  - Animals
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bridged-Ring Compounds
KW  - Cisplatin
KW  - Docetaxel
KW  - Humans
KW  - Male
KW  - Mice
KW  - Platinum
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Proto-Oncogene Proteins c-bcl-2
KW  - Taxoids
TI  - Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
TY  - research article
VL  - 79
ER  -